CareDx, Inc
CDNA
주식 순위
#4442
CareDx, Inc. is a global innovator specializing in the discovery, development,... CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
주가
$67.25
마지막 동기화: 2026-10-19
시가총액
$3.48B
변동 (1일)
5.08%
변동 (1년)
341.85%
국가
US
거래 CareDx, Inc (CDNA)
카테고리
Healthcare
CareDx, Inc (CDNA)의 P/E 비율
October 2026 기준 P/E 비율 TTM: 30.06
CareDx, Inc의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 30.06입니다. 2023년 말 기준 P/E 비율은 -3.39였습니다.
CareDx, Inc의 P/E 비율 기록 (2012 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 30.06 | 39.82% |
| 2024 | 21.50 | -734.14% |
| 2023 | -3.39 | -57.30% |
| 2022 | -7.94 | -89.75% |
| 2021 | -77.49 | -56.94% |
| 2020 | -179.95 | 334.79% |
| 2019 | -41.39 | 115.98% |
| 2018 | -19.16 | 521.35% |
| 2017 | -3.08 | 173.28% |
| 2016 | -1.13 | -79.55% |
| 2015 | -5.52 | -110.22% |
| 2014 | 53.99 | -386.60% |
| 2013 | -18.84 | 42.83% |
| 2012 | -13.19 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 36.15 | 20.27% |
US
|
|
| 39.77 | 32.31% |
US
|
|
| -290.26 | -1,065.54% |
US
|
|
| - | - |
CN
|
|
| 34.18 | 13.71% |
US
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.